TuHURA Biosciences (NASDAQ:HURA - Free Report) - HC Wainwright issued their Q3 2026 earnings per share estimates for TuHURA Biosciences in a research report issued on Thursday, April 3rd. HC Wainwright analyst R. Burns expects that the company will post earnings per share of ($0.10) for the quarter. HC Wainwright has a "Buy" rating and a $12.00 price objective on the stock. HC Wainwright also issued estimates for TuHURA Biosciences' Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.09) EPS, Q1 2027 earnings at ($0.09) EPS, Q1 2027 earnings at ($0.09) EPS and Q2 2027 earnings at ($0.09) EPS.
Other equities research analysts have also recently issued research reports about the company. RODMAN&RENSHAW raised TuHURA Biosciences to a "strong-buy" rating in a report on Thursday, December 19th. Rodman & Renshaw assumed coverage on TuHURA Biosciences in a research note on Thursday, December 19th. They set a "buy" rating and a $11.00 target price on the stock.
Read Our Latest Stock Report on HURA
TuHURA Biosciences Stock Up 5.1 %
NASDAQ:HURA traded up $0.19 during mid-day trading on Friday, hitting $3.94. The stock had a trading volume of 57,175 shares, compared to its average volume of 272,948. The stock's 50 day moving average is $3.37. TuHURA Biosciences has a 52 week low of $1.80 and a 52 week high of $7.93.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in HURA. Accent Capital Management LLC acquired a new stake in TuHURA Biosciences in the fourth quarter worth approximately $29,000. TT Capital Management LLC acquired a new stake in shares of TuHURA Biosciences in the fourth quarter valued at $41,000. Jefferies Financial Group Inc. bought a new position in TuHURA Biosciences during the fourth quarter valued at about $54,000. Bank of America Corp DE acquired a new position in TuHURA Biosciences during the fourth quarter worth about $59,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in TuHURA Biosciences in the fourth quarter worth about $61,000. 0.62% of the stock is currently owned by institutional investors.
About TuHURA Biosciences
(
Get Free Report)
TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
See Also
Before you consider TuHURA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.
While TuHURA Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
